March 26, 2021

Umair A. Shah, MD, MPH
Secretary of Health
Washington State Department of Health
111 Israel Rd SE
Tumwater, WA 98501

Dear Secretary Shah:

On behalf of the approximately 700 people living with cystic fibrosis in Washington, we write today to urge the state to ensure people with high-risk medical conditions—including cystic fibrosis—are prioritized for early access to COVID-19 vaccines. We recognize the monumentally difficult task public health officials face when creating allocation plans that are both equitable and actionable during this crisis, and we appreciate the immense effort state public health departments have put into creating plans to allocate limited supplies of COVID-19 vaccines. However, we are deeply concerned that the state’s vaccine plans would deny some people with CF the ability to access COVID-19 vaccines alongside others with high-risk conditions due to criteria related to multiple comorbid conditions.¹

Our comments below urge Washington to immediately revise its COVID-19 vaccine prioritization plan to ensure that individuals with one high-risk condition are able to access vaccines alongside those with multiple comorbidities.

**Background on Cystic Fibrosis and COVID-19**

The Cystic Fibrosis Foundation is a national organization actively engaged in the research and development of new therapies for cystic fibrosis—a rare, life-threatening genetic disease that affects more than 30,000 people in the United States. The buildup of thick, sticky mucus in the lungs characteristic of the disease makes people with CF particularly prone to chronic respiratory infections. These chronic infections are punctuated by pulmonary exacerbations, events that are a risk factor for an irreversible decline of lung function and associated with morbidity and mortality. A significant proportion of pulmonary exacerbations are triggered by respiratory viral infections. Continued progression of the disease can result in advanced lung disease so severe that lung transplantation may be the only life extending option.

The absent or malfunctioning protein that causes CF is also associated with a wide range of disease manifestations beyond the lungs, including pancreatic insufficiency that can lead to malnutrition, gastrointestinal issues, biliary cirrhosis, and diabetes mellitus.

While we have seen incredible progress in recent decades for those living with cystic fibrosis, COVID-19 represents a serious threat for this population. The strongest evidence to date on the threat COVID-19

poses to those with CF comes from a global analysis of 181 COVID-19 cases among people with CF.² From that analysis, it appears CF patients with advanced lung disease, those that are post-lung transplantation, and those with diabetes mellitus may be at risk of severe outcomes including death.

Due to the known risks posed by viral infections and multi-system manifestations of the disease described above, people with CF should be considered at increased risk of poor outcomes from COVID-19 infection and the Centers for Disease Control and Prevention (CDC) has listed CF as a condition that may put individuals at increased risk for worse outcomes.³

**Individuals with One High-Risk Condition Should be Prioritized for Access to COVID-19 Vaccines**

We urge Washington to give equal priority to anyone with a condition that puts them at high-risk for severe disease from COVID-19 instead of prioritizing those with two or more comorbid conditions. We recognize the need for sub-group prioritization due to limited vaccine supplies. However, a focus on multiple conditions neglects other indications of disease severity or vulnerability. For instance, those with CF with advanced disease may be particularly at risk. Nonetheless, under an allocation scheme prioritizing those with two or more high-risk comorbid conditions, individuals with advanced disease would receive a vaccine after someone with a body mass index above 30 and COPD. We believe that this scenario inappropriately disadvantages someone who should be prioritized for early access to a vaccine, and we recommend removing the criteria related to multiple conditions.

**********

Once again, we thank you for your attention and consideration of people with CF as you tackle these difficult issues. We look forward to working with you as the state continues to revise and develop further allocation recommendations for COVID-19 vaccines.

Sincerely,

Mary B. Dwight
Chief Policy and Advocacy Officer
Senior Vice President of Policy and Advocacy
Cystic Fibrosis Foundation

Alma Chavez, MD
Director, Pediatric CF Care Center
Providence Medical Group, Cystic Fibrosis Clinic
Spokane, WA

Moira L Aitken, MD
Director, Adult CF Care Center
University of Washington Medical Center
Seattle, WA

Ronald Gibson, MD
Director, Pediatric CF Care Center
Seattle Children’s Hospital
Seattle, WA

Jason B. Caboot, MD
Director, Pediatric CF Care Center
Madigan Army Medical Center
Joint Base Lewis-McChord, WA

Allison Lambert, MD
Director, Adult CF Care Center
Providence Medical Group, Cystic Fibrosis Clinic
Spokane, WA

---

CC: The Honorable Jay Inslee, Governor of Washington
Jamila Thomas, Chief of Staff, Governor’s Office
Sue Birch, Director, Washington State Health Care Authority
MaryAnne Lindeblad, State Medicaid Director, Washington Apple Health